510(k) Summary for the Sorin Group Deutschland GmbHJAN - 6 2011 (per 21 CFR 807.92 and

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/default.htm)

1. SPONSOR/APPLICANT

Sorin Group Deutschland GmbH

Lindberghstrasse 25

80939 Munich

Germany

Telephone:

011-49 (0)89 323 01 153

Facsimile:

011-49(0)89 323 01 333

Contact:

Renate Goebert

Date Prepared: January 4, 2010

2. DEVICE NAME

Proprietary Name:

Sorin B-Cares

Common/Usual Name: Venous blood gas module for heart lung machine; perfusion

monitoring device

Classification Name:

Cardiopulmonary bypass, on-line blood gas monitor (21

CFR 870.4330; Product code: DRY)

3. PREDICATE DEVICE/S

- Dideco Data Master, K001388
- Sorin B-Care₅ (Addition of an Optional Modular Accessory to the Stöckert S5 System), K092463)

4. DEVICE DESCRIPTION

Physical description

The Sorin B-Care₅ described in this 510(k) Premarket Notification is identical to the device that was cleared under K092463 and uses the same in-line sensors cleared under K001388.

How the device functions

When switched on, the Sorin B-Care₅ progresses from warm-through initialization self test while resting on the holder. When self test is successful, Sat- (venous

saturation) and Hct- (hematocrit) values are displayed. The sensor is then mounted on the disposable connector in the extra-corporal circuit. The B-Care₅ alerts (alarms or warns) the user if laboratory reference values have not been stored for venous O₂ saturation and hematocrit.

• Scientific concepts that form the basis for the device

The Sorin B-Care₅ monitors blood values via the sensor head with two LED sources and a receiver in contact with the optical window integrated into the venous connectors. Temperatures are monitored using thermistors in the venous probes. The technology of the Sorin B-Care₅ is based on the technology of the Dideco Data Master (Sorin Group Italia is the parent company of Sorin Group Deutschland GmbH and was formerly known as Dideco).

• Significant physical and performance characteristics of the device, such as device design, material used, and physical properties

The B-Care₅ is used for determining oxygen saturation, hematocrit, and temperature in the venous blood circuit. Specifications are provided in B-Care₅ Operating Instructions.

5. Intended Use/Indication for Use

The B-Care₅ is intended for use as a component part of or optional accessory to the Stöckert S5 system (or any compatible system using the S5 firmware versions of 3.0 or greater), during cardiopulmonary bypass for procedures up to six hours. The B-Care₅ is used exclusively for determining oxygen saturation, hematocrit value and temperature in the venous blood circuit.

6. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPARED TO THE PREDICATE DEVICE/S

The technological characteristics of the B-Care₅ are identical to those reported to the FDA in K092463 and substantially equivalent to those of the Dideco Data Master (K001388). All are firmware-controlled systems using the same in-line connectors with integral sensor probes. All devices read the data external to the blood circulation and display data digitally; all are controlled via touchscreen. Venous saturation and hematocrit values are calibrated to reference (laboratory) values. All provide trending of values and allow the user to program alarm limits. However, the Dideco Data Master can be used independently of a heart lung machine console, whereas the B-Care₅ cannot be used independently and must be used connected to a Sorin/Stöckert heart lung machine console.

Sorin B-Care₅ and Data Master specifications for the following are identical: saturation resolution, saturation accuracy, hematocrit resolution, and temperature resolution.

There are some minor differences in the operational specifications but all are within clinically relevant ranges. For example, the saturation range for the B-Care₅ has a wider range (0%-100%) than the Data Master (40%-100%); the B-Care₅ hematocrit range is 0% to 100% while the Data Master hematocrit range is 15% to 50%; the B-Care₅ temperature range is 0°C to 50°C while the Data Master temperature range is 10°C to 45°C. These wider ranges allow the perfusionist to operate and detect the specified parameters at lower and higher levels.

7. SUMMARY OF NON-CLINICAL PERFORMANCE TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE

The Sorin B-Care₅ was tested in conjunction with the heart lung machine for safety in accordance with IEC60601-1 (with National Deviations), for electromagnetic compatibility in accordance with IEC60601-1-2, and performance according to a formal prospectively defined functional acceptance test. Testing of the Sorin B-Care₅ (hardware, firmware, and performance) has demonstrated that the Sorin B-Care₅ fulfills prospectively defined performance criteria and that the System meets user needs.

8. SUMMARY OF CLINICAL TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE

Formal clinical testing of the Sorin B-Care₅ has not been performed. Therefore, this section does not apply.

9. SUMMARY OF OTHER INFORMATION

No information other than that described was provided.

10. CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL TESTS

Based on the non-clinical testing provided in this premarket notification, the Sorin B-Care₅ integrated with the Stöckert S5 performs in an identical manner as the B-Care₅ integrated with the C5, thus demonstrating that there are no differences and that the devices are substantially equivalent and perform in accordance with specifications.







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

Sorin Group Deutschland GmbH c/o Ms. Rosina Robinson Medical Device Consultants, Inc. 49 Plain Street North Attleboro, MA 02760

JAN - 6 2011

Re: K103168

Trade/Device Name: Sorin B-Care₅ Regulation Number: 21 CFR 870.4330

Regulation Name: Cardiopulmonary bypass on-line blood gas monitor

Regulatory Class: II Product Code: DRY Dated: October 26, 2010 Received: October 27, 2010

Dear Ms. Robinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

Page 2 – Ms. Rosina Robinson

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

June R. Vi Amer

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

JAN - 6 2011

510(k) Number (if known): 103168

Device Name:

Sorin B-Care₅

Indications for Use:

The B-Care₅ is intended for use as a component part of or optional accessory to the Stöckert S5 system (or any compatible system using the S5 firmware versions of 3.0 or greater), during cardiopulmonary bypass for procedures up to six hours. The B-Care₅ is used exclusively for determining oxygen saturation, hematocrit value and temperature in the venous blood circuit.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Cardiovascular Devices

510(k) Number <u>K103168</u>